top of page

MARGINAL ZONE LYMPHOMA

Overview

A  Phase 2 Open Label Randomized Study to Evaluate the efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea.

Do you Qualify?

​These questions require a yes answer to qualify.​

  • Are you at least 18 years of age?

  • Are resistant to or intolerant of Hydroxyurea, that is, fulfilling at least 1 of the following criteria:

  1.  Platelet count > 600× 109/L after 3 months of at least 2 g/day of HU (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's maximally tolerated dose if that dose is < 2 g/day.

  2.  Platelet count > 400 × 109/L and WBC count < 2.5 × 109/L or hemoglobin (Hgb) < 10 g/dl at any dose of HU.

  3.  Presence of leg ulcers or other unacceptable muco-cutaneous manifestations at any dose of HU.

  4.  HU-related fever.

  • Platelet count > 650 × 109/L at screening

  • WBC > 11.0 × 109/L at screening.

​These questions require a no answer to qualify.​

  • Are you currently pregnant, plan to become pregnant or breastfeeding?

  • Are you currently suffering from any heart diseases or low liver function?

  • Are you currently suffering from any major illnesses that may require extended hospitalization?

  • Are you currently suffering from an active alcohol or drug addiction?

If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.

bottom of page